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The history of the neglected tropical disease movement is seen through the lens of authors who worked during
the last 4 decades in different roles and in different settings, from Western-based laboratories to clinical roles
in endemic countries and in critical policy roles in the World Health Organization (WHO). The authors seek to
identify key players from the introduction of the word ‘neglected’ by the late Kenneth Warren in his Rockefeller
Foundation–supported Great Neglected Diseases of Mankind movement through to the more recent develop-
ments after the London Declaration of 2012. The role of the various actors—endemic countries, major pharma-
ceutical companies, the WHO, non-government development organizations, bilateral donors and academia—
are discussed. The critical events and decisions are highlighted that were essential enabling factors in creating
a viable and successful movement and with a resultant massive global public health and antipoverty impact.
The importance of advocacy is emphasized in creating the momentum to establish a globally recognized public
health ‘brand’ as a target in the United Nations Sustainable Development Goals.
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Introduction: 20th century origins
Estimates suggest that approximately 1 in 10 of the world’s
population live in extreme poverty (on <$1.90/d), with most
infected with one or more of the neglected tropical diseases
(NTDs). Indeed, the term ‘neglected tropical diseases’ describes
a transition from the 19th century study of tropical diseases
to one that prioritized the plight of neglected populations liv-
ing in extreme poverty.1 During the late 1970s, Kenneth S. War-
ren, Head of Health at the Rockefeller Foundation, launched
a network of research laboratories devoted to the study of
parasitic diseases. He branded them as ‘great neglected dis-
eases (GND) of mankind’ to incentivize scientists who previ-
ously worked on model organisms to apply their knowledge
to infectious diseases of the poor. Warren recognized how dis-
eases such as schistosomiasis and malaria were ignored by the
evolving disciplines of immunology and molecular biology.2–4
He was successful in making a humanitarian appeal to these
scientists. For example, Warren pointed out how schistosomia-
sis caused liver disease in 100 million people and yet the total
research expenditures worldwide for this disease were <$5 mil-
lion3 and schistosomiasis was not prioritized by the commu-
nity committed to the study of hepatic disease. Many scientists
began their basic research through Warren’s GND Network,5,6
recognizing the humanitarian benefits of coming together; this
led to the grouping of these conditions under the moniker of
‘neglected’.
In parallel with Warren’s initiative in 1976, the World Health
Organization (WHO) Special Programme for Research and Train-
ing in Tropical Diseases (TDR) was established under the auspices
of the World Bank and United Nations Development Programme
(UNDP), a partnership of multilateral and bilateral donors and
disease-endemic countries to study a similar portfolio of dis-
eases under the successive leadership of Howard Goodman,
Adetokundu Lucas and Tore Godal.
In Africa, the British government and the European schools
of tropical medicine were also supporting research institutions
in endemic areas, but there was an equal urgency to simulta-
neously prioritize low-cost interventions with existing medicines.
Solving tropical disease dilemmas required strategies that would
be effective and yet inexpensive. A hint of things to comewere ini-
tial efforts to promotemass treatment and worm control with an
anthelminthic drug. The concept was pioneered by Frank Hawk-
ing during the 1950s and 1960s using diethylcarbamazine citrate
(DEC) for lymphatic filariasis (LF)7,8 and by the Chinese using DEC-
fortified salt for filariasis control in a population of 350 million
people.9 It took some 50 y for this concept to be accepted and
implemented globally.
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Preventive anthelminthic chemotherapy:
mass treatment without individual diagnosis
Despite the efforts highlighted above, by the 1990s there
remained a dearth of funding for both research and treatment of
diseases of poor populations and therefore no significant expan-
sion in the number of scientists interested or able to work on
these conditions. By the turn of the millennium, the study of
infectious tropical pathogens had fallen behind other areas of the
biomedical sciences. Parasites were not easily amenable tomod-
ern molecular and immunological methods or rapidly accelerat-
ing advances in transmission dynamics and mathematical mod-
eling.6,10,11 Then two important developments occurred.
The first major advance in the diseases of the poor was
the entry of multinational pharmaceutical companies, which
began turning their attention to the treatment of global tropi-
cal infections. Early results from TDR-sponsored studies on lep-
rosy resulted in the development of multidrug therapy (MDT;
rifampicin, clofazimine and dapsone), donated by Novartis (then
Ciba-Geigy) in 2000 following approval of MDT in 1984 by the
WHO. Increasingly it became recognized thatmultinational phar-
maceutical companiesmight play a significant humanitarian role
in the mass treatment of global human parasitic infections. A
pioneer was Nobel Laureate William Campbell, who led efforts at
MSD to develop and test anthelminthic drugs of the avermectin
class following their initial discovery and isolation from Strep-
tomyces bacteria by Satoshi Ōmura and colleagues in Japan.12
Initial work focused on veterinary applications to treat livestock
for intestinal helminth and ectoparasite infections. Soon clini-
cal trials confirmed the therapeutic effect of the drug ivermectin
in treating human onchocerciasis (river blindness),13 prompting
MSD Chief Executive Officer Roy Vagelos to announce the dona-
tion of Mectizan (ivermectin) ‘for as long as needed’ through the
Mectizan Donation Program.14 Both Mectizan and MDT donations
shaped a new paradigm in which a drug discovered or developed
by amajor pharmaceutical companymight be redirected to treat
human diseases in global programs of mass drug administration.
The use of Mectizan became instrumental for the success
of the World Bank’s Onchocerciasis Control Programme (OCP)
in West Africa in its later stages when it was employed to
supplement vector control to reduce microfilarial loads.15 The
Mectizan Donation Program was an enabling factor when the
World Bank created the African Programme for Onchocercia-
sis Control (APOC) in 1995, allowing expansion of onchocercia-
sis programmes based on the concept of community-directed
treatment with ivermectin (CDTi), an approach developed by
the WHO/TDR, OCP and APOC-sponsored research in all of the
remaining onchocerciasis-endemic countries in Africa.16 The ini-
tial objective of the APOC was to create sustainable Mecti-
zan delivery systems using CDTi within 5 y.16 In addition, the
multidonor financing of the APOC was supplemented by the
strong commitment of a number of non-government develop-
ment organizations (NGDOs) who assisted in the implementation
of country programmes while also providing some 25% of the
financing.17
At the same time, a programme for the control of onchocer-
ciasis in the six endemic countries in the Americas (Onchocercia-
sis Elimination Programme in the Americas [OEPA]) was launched
based on Mectizan treatment alone given twice yearly.
A second accelerant was the theoretical framework of pop-
ulation and transmission dynamics models of human helminth
infections shaped by Anderson and May10 and Schad and Ander-
son,11 with evidence that proof-of-concept of such constructs
could be successfully applied to the deworming of children with
intestinal helminths.
Such efforts prompted the initial donation ofmebendazole, by
Johnson & Johnson, and later albendazole by GlaxoSmithKline.18
In parallel, Davis and Wegner19 showed the potential impact of
praziquantel on human schistosomiasis, and some 25 y later
the Schistosomiasis Control Initiative, seed funded by the Bill &
Melinda Gates Foundation (BMGF), was able to scale up the use
of praziquantel, eventually leading to a donation of the drug
by Merck KGaA. A major result in 2007, through efforts by the
WHO and the Financial Times, was that Merck KGaA signed an
agreement for the donation of praziquantel for schistosomia-
sis for school-age children. Initially 20 million tablets per year
were donated, but by 2017 the donation had reached 250 mil-
lion tablets.
Meanwhile, Mabey et al.20 led efforts to examine mass treat-
ment of trachoma with azithromycin, leading to a donation of
that drug by Pfizer through the International Trachoma Initiative
(ITI) founded by Joseph Cook, which also increased to >120 mil-
lion doses annually by 2015. In 2000, the Global Programme to
Eliminate Lymphatic Filariasis (GPELF) was launched following a
World Assembly Resolution in 1997 calling for elimination of the
disease as a public health problem. Combinations of either alben-
dazole and diethylcarbamazine (in Asia) or albendazole and iver-
mectin (in Africa in countries endemic for onchocerciasis) were
then employed to treat millions of people annually to protect
them from LF following studies carried out through funding from
the TDR.21
NTDs: a pro-poor framework for the
new millennium
Reaching the poorest populations and treating and preventing
disabling infections became an aspirational advocacy strategy.
Decision makers began to recognize that implementation of
mass treatment programmes could promote economic devel-
opment. The economist Jeffrey Sachs proposed linking Africa’s
development to the control of malaria and other diseases22,23
and chaired a Commission on Macroeconomics and Health.24,25
The commission report was a landmark document linking global
health to poverty, also explaining how diseases such as malaria
and human immunodeficiency virus (HIV)/acquired immune defi-
ciency syndrome (AIDS) trapped populations living in low- and
middle-income countries in a cycle of poverty.24,25 It also helped
to spark the elevation of infectious disease control to global policy
makers, leading to its inclusion as Millennium Development Goal
(MDG) 6: ‘To combat AIDS, malaria, and other diseases’. Accord-
ingly, Sachs, as adviser to the United Nations (UN) Secretary-
General, initiated the formation of the Global Fund to Fight AIDS,
Tuberculosis and Malaria as a financial instrument to support
countries in controlling these so-called big three diseases. How-
ever, it also became apparent that the Global Fund portfolio
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The MDG 6 focused on HIV/AIDS and malaria at the expense
of ‘other diseases’, including polio. Relegating parasitic infec-
tions such as schistosomiasis, hookworm and LF to the ‘other
diseases’ essentially left more than a billion people unserved
and unrepresented. In response, individual scientists began
advocating how particular diseases, such as LF, onchocerciasis,
schistosomiasis, trachoma and hookworm infection deserved
recognition as poverty-causing conditions.26,27 Neglected dis-
ease advocates further emphasized how interventions for these
parasitic diseases, especially throughmass drug administration28
or new vaccines29 would enhance development. Fortunately,
coinciding with the launch of the MDGs, the new BMGF began
the first of some of its major global health contributions to NTDs
by supporting academic institutions and NGDOs not only for
research on the basic science of NTDs but, especially importantly,
for operational research to ensure that the specific, real-world
challenges of NTD programmes were recognized and met (e.g.
where the diseases are found, how to identify and treat entire
at-risk populations, how to ensure population compliance, how
to define and meet target thresholds, what diagnostic tools and
sampling strategies are required and available, etc.). Without
answers to such questions, workable programmes cannot be
developed, and without workable programmes, long-term sup-
port cannot be sustained. The BMGF also committed support for
implementation of the OEPA and the Guinea Worm Eradication
Programme through the Carter Center.
Amajor turning point in global interest in tropical diseases was
the appointment in 2003 of J. W. Lee as Director General of the
WHO. Lee had experience working in leprosy in the Republic of
Korea as a young medical officer. At the WHO as Director Gen-
eral, Lee restructured the communicable diseases area as one of
the top priorities together with the ‘3 by 5’ AIDS treatment cam-
paign. In 2003, Hiroyoshi Endowas chargedwith reorganizing this
area of work, leading to renewed interest by the WHO’s member
states, donors, the pharmaceutical industry, academia andworld
experts.
As a result ofmeetings in Berlin organized by theWHO and the
Gesellschaft für Technische Zusammenarbeit (GTZ) in 2003 and
2005, the current framework of the NTDs began to take shape.
In a 2004 Lancet paper,30 Molyneux pointed out that huge suc-
cesses had already been achieved in combatting several tropi-
cal infections, listing filariasis in China, the OCP in West Africa,
Chagas’ disease in the Southern Cone countries of the Ameri-
cas via indoor residual spraying, leprosy with MDT and progress
in Guinea worm eradication initiated through the advocacy of
former-President Jimmy Carter in the late 1980s during the Inter-
national Water Decade. The major tenets of the concept of the
NTDs were then detailed in two back-to-back papers published
in the open access journal PLoS Medicine in 2005 and 2006.31,32
These became the first two papers indexed in PubMed specifically
referring to NTDs, reporting on major features that included the
following observations:
 There were approximately 13 diseases of the poor that could
be branded as NTDs due to their high prevalence and perva-
siveness among populations living in extreme poverty.
 These diseases geographically overlapped and were co-
endemic such that impoverished populations were polypar-
asitized.
 The effects of polyparasitism translated into lost productiv-
ity and disability (often irreversible), with consequential socio-
economic decline.
 At least 7 of the 13 diseases could be targeted simultane-
ously in an inexpensive ‘rapid impact’ package of medicines
donated by pharmaceutical companies or available as low-
cost generics.
A further consideration was how NTDs also complicated the
treatment of malaria and HIV/AIDS through synergistic and addi-
tive effects operating through anaemia and altered host immune
responses. Examples included the combination of hookworm,
schistosomiasis and malaria in pregnancy or the role of female
genital schistosomiasis in promoting susceptibility to HIV/AIDS.33
Taking action: translating science into policy
and practice
Efforts to redirect the ‘other diseases’ of the MDGs towards an
NTD ‘brand’ and offer low-cost solutions were mostly led by aca-
demic scientists working with the WHO.34 At that point there
was no roadmap for transitioning the published scientific arti-
cles in biomedical journals into global action. However, in the
absence of an established advocacy network, scientists work-
ing on the NTDs recognized a new reality that they needed to
lead such efforts and spearhead implementation. They created a
unique dynamic in which scientists began working directly with
leaders of the US Congress and the UK Parliament to allocate
funding to support the scale-up of rapid impact packages of
donated medications targeting NTDs.31–34 The WHO responded
by forming a new Department of NTDs following the 2005
Berlin meeting. Over this period, scientific findings rapidly tran-
sitioned into global health policy on several fronts: in the USA
and UK, the WHO and its regional offices, increased pharmaceu-
tical company interest, commitment from NGDOs and the exist-
ing disease-specific partnerships. The focus was a package of
simple treatments given annually that could target seven major
NTDs: the three soil-transmitted helminthiases, LF, onchocer-
ciasis, schistosomiasis and trachoma. Because of drug dona-
tions from the pharmaceutical companies, the package could be
administered for <$1 per person and often for <$0.40.32,33,35,36
Thesemedicines included albendazole,mebendazole, praziquan-
tel, DEC, ivermectin and azithromycin. It became increasingly
apparent to global policymakers that this approach represented
one of the most cost-effective ‘best buys’ in global public
health.37 In addition, Sanofi-Aventis committed to donate ther-
apies for human African trypanosomiasis and leishmaniasis and
Gilead donated its new product ambisome for visceral leishma-
niasis.
The next step was to mobilize resources to deliver these
medicines and support the health ministries in disease-endemic
nations. A critical impact was the decision by the G8 in Hokkaido
(Japan) in 2008 to help to control and eliminate several NTDs.
This was initiated by the personal commitment of Prime Minis-
ter Hashimoto of Japan, advised by some committed parasitol-
ogists led by the late Tsutomu Takeuchi. It was initially raised as
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was endorsed at the Birmingham (UK) Summit in 1998 to tackle
the issue globally. The Global Parasite Control for the 21st Century
initiative, better known as the Hashimoto Initiative, was a critical
visionary initiative not immediately endorsed by many G8 states.
However, it did stimulate increased advocacy efforts in several G8
countries following the decision in Hokkaido 10 y later. Initially
efforts were focused on the US and UK governments, and later
private sources of funding. In the USA, Peter Hotez and Eric Otte-
sen worked through the Global Health Council (under the direc-
tion of Niels Dulaire) to explain to the Bush White House and key
congressional leaders about the highly cost-effective opportu-
nity to control NTDs. They persuaded Congress in 2005 to provide
initial financial support to programmes targeting NTDs by tak-
ing advantage of the donated medicines available. In 2006, the
US Agency for International Development (USAID) established an
NTD programme for this purpose, allocating $100 million over
5 y to operate through contractors, NGDOs and the ministries of
health in disease-endemic countries.
In 2005, Hotez worked with Gavin Yamey from the Public
Library of Science (PLoS) to secure seed support from the BMGF
and create PLoSNeglected Tropical Diseases, the first open access
journal for NTDs,38 in addition towriting a book entitled, Forgotten
People Forgotten Diseases.39 The BMGF also supported advocacy
and resource mobilization for NTDs by establishing a Global Net-
work for NTDs, initially based inWashington, DC,33,40 prior to tran-
sitioning it to Uniting to Combat NTDs in London, together with an
END (End Neglected Diseases) Fund based in New York. Follow-
ing the transition from the Bush to the Obama administration,
Ezekiel Emanuel and Office of Management and Budget Direc-
tor Jack Lew and others helped to maintain enthusiastic support
for NTDs. A further dimension towards advancing pro-poor poli-
cies was the realization that NTDs are also widespread among
the poor living in the USA41 and the G20 group of nations, a con-
cept referred to as ‘blue marble health’ to differentiate it from
traditional global health norms of developed versus developing
countries.41,42
In the UK, Alan Fenwickwas able toworkwith the teamwriting
the Commission for Africa Report launched by PrimeMinister Tony
Blair at the Gleneagles G8 Summit in 2005 to obtain recognition
for the need to address NTDs. Ultimately, through the UK Depart-
ment for International Development (DFID), the UK expanded
initial support from USAID and the BMGF. Funds from these orga-
nizations helped to either create or sustain the Schistosomiasis
Control Initiative (SCI, founded by Alan Fenwick and initially based
at Imperial College, London) and the Lymphatic Filariasis Pro-
gramme based at the Liverpool School of Tropical Medicine under
David Molyneux and funded by the DFID in partnership with Glax-
oSmithKline. Molyneux and Fenwick were then asked in 2008 to
prepare suggestions for how UK funding could be best deployed
to support NTD programmes, leading to an initial £50 million
commitment that was subsequently increased to an additional
£195 million (announced at the meeting in London in January
2012). After 2010, a key individual was Sir Stephen O’Brien, as a
minister in the DFID (later UNUndersecretary General for Human-
itarian Affairs), who recognized the cogent arguments from NTD
advocates for the health and development objective as an exem-
plar of effective partnerships and the value of money provided by
donor support. His initiative led to an important advocacy forum
being established in the UK parliamentary system ‘The All-Party
Committee on Malaria and NTDs’, which continues to meet
regularly.
The recognition that some NTDs that caused significant mor-
tality, notably the leishmaniases and trypanosomiases, required
medical supervision for treatment and depended on drugs that
were expensive, toxic to patients and involved long courses of
treatment led to the establishment of the Drugs for Neglected
Disease Initiative (DNDi), a product development partnershipwith
the objective of developingmore effective and safer drugs initially
for the leishmaniases and trypanosomiases, but which has now
expanded to include conditions such as mycetoma and amacro-
filaricide for onchocerciasis and filariasis. Later, the Foundation
for Innovative New Diagnostics (FIND) was created as a product
development partnership (PDP) for diagnostics, as were several
PDPs for ‘antipoverty’ vaccines, including the Infectious Disease
Research Institute (IDRI, founded by Steve Reed), Human Hook-
worm Vaccine Initiative (HHVI, founded by Peter Hotez), which
later became the Texas Children’s Center for Vaccine Develop-
ment, and the International Vaccine Institute (IVI).1
In Geneva, following the 2005 Berlin meeting at the WHO,
J. W. Lee and Anarfi Asamoa-Baah worked with Lorenzo Savioli to
establish an inaugural Department of NTDs to provide technical
support for integrated mass drug administration, later renamed
preventive chemotherapy or preventive treatment, and diseases
that required more intensive clinical management. Initially the
WHO adopted the 13 diseases but subsequently expanded this
list to 20 conditions.43 A turning point in the efforts against these
diseases was achieved after the first Global Partner’s Meeting
convened by the WHO in 2007, an initiative outside any for-
mally structured partnership that resulted in a shared commit-
ment to support the WHO’s strategies, goals and targets.44 Key
to the political support by all partners was the endorsement by
the WHO member states of a series of specific resolutions for
each NTD in the WHO portfolio to ensure political backing for dis-
ease prevention, control, elimination and eradication strategies.
The capstone of this essential work was the approval in 2013 of
an overarching comprehensive resolution on NTDs (WHA 66.12,
World Health Assembly [WHA] Resolutions on Neglected Trop-
ical Diseases: 1948–2019, available from: https://www.who.int/
neglected_diseases/mediacentre/resolutions/en/) that ensured
the full backing of theWHO’s governing bodies of all the key pub-
lic health strategies developed by the NTD community for >40 y.
The London Declaration
As the establishment of the NTDs as a credible ‘brand’ devel-
oped,31–33 the NGDOs became increasingly important players in
support of country implementation. Beyond SCI and the LF pro-
grammes, Sightsavers, UK, began supporting wider issues of dis-
ability where previously it had focused on the visually impaired.
Large NGDOs such as Helen Keller International (HKI), Christoffel-
Blindenmission (CBM), the Carter Center, the Task Force for Global
Health and the leprosy NGDOs, through the International Fed-
eration of Anti-Leprosy Associations, joined the NTD advocacy
movement, as did several large USAID contractors such as RTI
International and FHI360, eventually leading to the creation of
a more formally structured partnership, the NTD Network (NNN),
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lishment of the Coalition for Operational Research for NTDs, in
the Task Force for Global Health, coordinated the drive to address
the operational research questions and ensure the research
community focussed on programmatically relevant questions
tied to achieving the 2020 goals was also a pivotal event. It
also linked three key donors—the BMGF, USAID and DFID—in
their commitment to support and improve the scale-up of pro-
grammes of new interventions while ensuring improved donor
coordination.
The years 2002–2012 were a success for the advocacy and
implementation of preventive treatment with the drugs prazi-
quantel (against schistosomiasis), ivermectin (against river blind-
ness), ivermectin and albendazole in Africa (against LF), DEC and
albendazole (against LF outside of Africa), azithromycin (against
trachoma) and mebendazole and albendazole (against intesti-
nal helminths). The numbers reached by organizations assist-
ing ministries of health and education in the endemic countries
increased asmoremedications were donated by pharmaceutical
companies.
In January 2012, a meeting in London, chaired by Bill Gates,
was convened to bring together the main players in the sup-
port of NTDs: the WHO, the BMGF, the USA and UK as bilateral
donors, NGDOs and the pharmaceutical industry. The meeting
and resulting London Declaration established not only increased
commitment, but also Uniting to Combat NTDs as an advocacy
group with the mandate to expand the partnerships and draw
in new partners and donors (www.unitingtocombatntds.org).
By 2015, a critical milestone was reached, when the numbers
of annual treatments reached more than one billion people
for NTDs, primarily with donated essential medicines, often in a
package of interventions as first outlined in 2005. Today it is worth
noting that much of the leadership of this system of organiza-
tions committed to NTDs has been and continues to be shaped by
charismatic women. The visionary leadership of Uche Amazigo,
Director of the APOC, who passionately articulated the personal
stories of onchocerciasis patients; Julie Jacobson and Katey
Owen of the BMGF; Mwele Malecela, who directed the Tanzania
LF programme and is now the director of the WHO NTD Depart-
ment; Lisa Rotondo, who heads the RTI NTD programme; Maria
Rebollo Pollo, who is responsible for the Expanded Special Project
for Elimination of NTDs (ESPEN) of WHO/AFRO; Wendy Harrison,
who leads the Schistosomiasis Control Initiative Foundation;
Thoko Elphick-Pooley, of Uniting to Combat NTDs; Ellen Agler,
chief executive officer of the END Fund; Emily Wainwright, at
USAID; Delna Ghandi of DFID and Caroline Harper of Sightsavers.
Following progress in the goals and targets of the 2012 WHO
roadmap that inspired the London Declaration and the scale-
up several new key themes began to emerge. The major suc-
cesses achieved by endemic countries in achieving elimination
of some NTDs stimulated increased interest and justified invest-
ment in programmes building a firm evidence-based platform
for continued support. In addition, there is the realization that
NTDs disproportionately affect girls and women living in poverty,
perhaps best illustrated by the plight of some 40 million African
adolescent girls and young women affected by female genital
schistosomiasis.44 Despite an abundance of evidence that female
genital schistosomiasis increases the chance of HIV/AIDS infec-
tion, it remains difficult to persuade global policymakers to link
programs for these conditions. Thus a tragic firewall remains
separating praziquantel for schistosomiasis from the US Presi-
dent’s Emergency Plan for AIDS Relief and the Global Fund. Yet
another concern is the increasing awareness of how NTDs affect
mental health through both direct effects on the central ner-
vous system and through their stigmatizing and psychological
effects.45,46 NTD control has the potential to greatly reduce the
global burden of mental illness.
Finally, there is the recent finding that as mass treatment
expands and has reached more than one billion people annually
we are beginning to see important but unexpected collateral ben-
efits of these programs, leading to the control and elimination of
NTDs such as yaws and scabies (later added to the WHO’s port-
folio of NTDs ), as well as overall reductions in child morbidity and
mortality through mechanisms not yet determined.47 By the end
of the 2010s there was growing awareness that we might see
both the control and even elimination of some key NTDs as well
as improve the overall health of girls and women, and young chil-
dren, while making a significant impact on global mental health.
Future directions
There was a sense of optimism that substantial progress had
beenmade towards the elimination of several NTDs, including LF,
onchocerciasis and trachoma, while promising progress in coun-
tering the scourge of skin NTDs, notably scabies and yaws, has
been achieved. The numbers of new cases are at an historic
low and a new oral treatment, fexinidazole, has been approved
for use while new and exciting technologies for diagnostics and
monitoring are in the development pipeline. New efforts to doc-
ument the impact of these activities on reducing poverty levels
were under way. The number of people living in extreme poverty
has fallen dramatically since 2000, to the point where <750 mil-
lion people lived below the World Bank poverty level of $1.90/d.
For a period of 5 consecutive years, until the end of 2019, >1 bil-
lion people had received NTD treatments.
However, in January 2020, coronavirus disease 2019
(COVID-19) emerged from China, becoming a global pan-
demic. Indeed, the case has been made that COVID-19 itself
is a health disparity and an NTD.48 The COVID-19 pandemic of
2020 has disrupted programmes of mass drug administration
and other NTD control measures.49 Alternative approaches for
ensuring access to preventive chemotherapy have been devel-
oped by the WHO in concert with member states, implementing
agencies, the pharmaceutical industry and NGDOs developing
a ‘hybrid’ approach.50 There is a serious risk NTDs will rebound
in areas where effective control or elimination had occurred
pre-COVID-19. The re-emergence of NTDs in some settings,
be it due directly to COVID-19, to health system interruptions
from war and political collapse,51 from demographic change
such as urbanization in African and Asian megacities52,53 or
climate change,54 can be predicted. The NTD community has
engaged with the WHO in developing the new WHO/NTD Road
Map 2021–2030, now endorsed by the World Health Assembly,
and can take credit for maintaining the momentum during the
last decade, but ultimate success in controlling or eliminating
NTDs will depend on overcoming the potent 21st century realities
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determinants of transmission54,55 in endemic countries to make
the road map a reality.
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